Current and Potential Epigenetic Targets in Multiple Myeloma

Abstract

Despite recent advances in therapy, subgroups of multiple myeloma continue to have a poor prognosis. Numerous epigenetic changes have been described and occur as both etiologic and secondary events, making myeloma a good disease in which to understand the role of epigenetic therapies. Here, we describe a number of current and potential epigenetic targets in myeloma.

Keywords::

• bromodomain inhibitor
• chromatin
• DNA methyltransferase inhibitor
• histone deacetylase inhibitor
• histone demethylase inhibitor
• histone methyltransferase inhibitor
• multiple myeloma

Financial & competing interests disclosure

The Institute of Cancer Research has a commercial interest in the development of epigenetic therapies. C Pawlyn is a Wellcome Trust Clinical Research Fellow. FE Davies is a CRUK Senior Cancer Fellow. The Centre for Myeloma Research is supported by Myeloma UK. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The Institute of Cancer Research has a commercial interest in the development of epigenetic therapies. C Pawlyn is a Wellcome Trust Clinical Research Fellow. FE Davies is a CRUK Senior Cancer Fellow. The Centre for Myeloma Research is supported by Myeloma UK. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.